Company attributes
Other attributes
Cynapsus Therapeutics is a specialty pharmaceutical company developing oral drug treatments for Parkinson's disease. Cynapsus Therapeutics was founded in 1984 by Anthony Giovinazzo and is headquartered in Toronto, Ontario, Canada.
Cynapsus Therapeutic's drug candidate for the treatment of Parkinson's disease is called APL-130277 and is a sublingual form of apomorphine; a common drug used to treat Parkison's disease that is administered to patients through the gastrointestinal system.
On September 1, 2016 Sunovion Pharmaceuticals acquired Cynapsus Therapeutics to expand its own drug portfolio to treat diseases on the central nervous system. Sunovion Pharmaceuticals purchased Cynapsus Therapeutics for approximately $624 million at $40.50 per share in cash.
